Evidence map›Paper›PMID 34929348›Full record

ReviewAgeing research reviews2022

A tale of two systems: Lessons learned from female mid-life aging with implications for Alzheimer's prevention & treatment.

Aarti Mishra, Yiwei Wang, Fei Yin, Francesca Vitali, Kathleen E Rodgers, Maira Soto, Lisa Mosconi, Tian Wang, Roberta D Brinton

Open access · hybridAbstract readReview
In one paragraph

Review in Ageing research reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Sex andInternational journal of molecular sciences · 2025
    Article
  13. Age of menopause and dementia risk in 10,832 women from the Swedish Twin Registry.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Aarti MishraCenter for Innovation in Brain Science, University of Arizona, Tucson, AZ 85719, USA.
Yiwei WangCenter for Innovation in Brain Science, University of Arizona, Tucson, AZ 85719, USA.
Fei YinCenter for Innovation in Brain Science, University of Arizona, Tucson, AZ 85719, USA.
Francesca VitaliCenter for Innovation in Brain Science, University of Arizona, Tucson, AZ 85719, USA.
Kathleen E RodgersCenter for Innovation in Brain Science, University of Arizona, Tucson, AZ 85719, USA.
Maira SotoCenter for Innovation in Brain Science, University of Arizona, Tucson, AZ 85719, USA.
Lisa MosconiDepartment of Neurology, Weill Cornell Medicine, New York, NY 10021, USA.
Tian WangCenter for Innovation in Brain Science, University of Arizona, Tucson, AZ 85719, USA.
Roberta D BrintonCenter for Innovation in Brain Science, University of Arizona, Tucson, AZ 85719, USA. Electronic address: rbrinton@arizona.edu.
Center for Innovation · USUniversity of Arizona · USWeill Cornell Medicine · US

Funding

Timing of Menopausal Hormone Therapy across Perimenopause to Menopause Transition: Neuroimmune System in BrainP01AG026572 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Adam C. Raikes · 2006 to 2026
$53.7M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI ALIREZA ATRI · 2021 to 2026
$24.9M
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal EndophenotypeR01AG057931 · NIA · UNIVERSITY OF ARIZONA · PI BRINTON, ROBERTA EILEEN, CHANG, RUI · 2018 to 2022
$6.0M
Aging and Estrogenic Control of the Bioenergetic System in BrainR37AG053589 · NIA · UNIVERSITY OF ARIZONA · PI ROBERTA EILEEN BRINTON · 2017 to 2026
$4.2M
NIA NIH HHS P01 AG026572NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG057931NIA NIH HHS R37 AG053589
6 · The paper itself

Abstract

Neurological aging is frequently viewed as a linear process of decline, whereas in reality, it is a dynamic non-linear process. The dynamic nature of neurological aging is exemplified during midlife in the female brain. To investigate fundamental mechanisms of midlife aging that underlie risk for development of Alzheimer's disease (AD) in late life, we investigated the brain at greatest risk for the disease, the aging female brain. Outcomes of our research indicate that mid-life aging in the female is characterized by the emergence of three phases: early chronological (pre-menopause), endocrinological (peri-menopause) and late chronological (post-menopause) aging. The endocrinological aging program is sandwiched between early and late chronological aging. Throughout the three stages of midlife aging, two systems of biology, metabolic and immune, are tightly integrated through a network of signaling cascades. The network of signaling between these two systems of biology underlie an orchestrated sequence of adaptative starvation responses that shift the brain from near exclusive dependence on a single fuel, glucose, to utilization of an auxiliary fuel derived from lipids, ketone bodies. The dismantling of the estrogen control of glucose metabolism during mid-life aging is a critical contributor to the shift in fuel systems and emergence of dynamic neuroimmune phenotype. The shift in fuel reliance, puts the largest reservoir of local fatty acids, white matter, at risk for catabolism as a source of lipids to generate ketone bodies through astrocytic beta oxidation. APOE4 genotype accelerates the tipping point for emergence of the bioenergetic crisis. While outcomes derived from research conducted in the female brain are not directly translatable to the male brain, the questions addressed in a female centric program of research are directly applicable to investigation of the male brain. Like females, males with AD exhibit deficits in the bioenergetic system of the brain, activation of the immune system and hallmark Alzheimer's pathologies. The drivers and trajectory of mechanisms underlying neurodegeneration in the male brain will undoubtedly share common aspects with the female in addition to factors unique to the male. Preclinical and clinical evidence indicate that midlife endocrine aging can also be a transitional bridge to autoimmune disorders. Collectively, the data indicate that endocrinological aging is a critical period "tipping point" in midlife which can initiate emergence of the prodromal stage of late-onset-Alzheimer's disease. Interventions that target both immune and metabolic shifts that occur during midlife aging have the potential to alter the trajectory of Alzheimer's risk in late life. Further, to achieve precision medicine for AD, chromosomal sex is a critical variable to consider along with APOE genotype, other genetic risk factors and stage of disease.

Indexed as

Alzheimer DiseaseAgingApolipoprotein E4BrainFemaleHumansKetone BodiesMaleApolipoprotein E4Ketone BodiesAgingAlzheimer’s diseaseAPOEInflammationMetabolismSex difference

Identifiers

PMID34929348
PMCPMC8884386
OpenAlexW4200039983

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.